Proud and grateful to see this work published:
jitc.bmj.com/content/13/12/e…
What started in 2018 at
@theNCI as an idea I kept returning to—how do we create a shared, reproducible language for increasingly complex immunohistochemistry and immunofluorescence assays?—has grown into a truly global, multi-specialty, multi-institutional collaboration.
This initiative was initially supported by
@abcam, then brought to the
@sitcancer, where it evolved into a broad effort spanning academia, pharma, and industry, supported by the SITC Pathology Task Force and strongly advocated for by
#JEDIs. None of this would have been possible without the exceptional leadership and coordination of the SITC staff, and the commitment of every contributor involved.
I am deeply honored to have worked alongside this extraordinary group of co-authors:
Carlo Bifulco
@CarloBiful63522, Jaime Rodriguez, M.D., poh sheng JOE YEONG
@JoeYeong, Guray A. Akturk, Michael Angelo, Carmen Ballesteros-Merino, PhD, Peter Bankhead
@petebankhead, Subham Basu, Jorge Blando, Saska Brajkovic, Marco Cassano, Benjamin J. Chen, Ahmet F Coskun, Tricia R. Cottrell, Carlos E. De Andrea, Robin Edwards, Colt Egelston, Logan Engle, Marc S. Ernstoff, Rong Fan, Michael Feldman, Bernard A. Fox PhD
@BernardAFox, Jerome Galon, Robyn Gartrell, Sacha Gnjatic, Benjamin Green, James Gulley MD PhD FACP
@gulleyj1, Anne Hellebust, Stephen Hewitt, Travis J. Hollmann, MD, PhD, Lucas A. Horn, William J. Howat, Clifford Hoyt, Shawn Jensen, Arutha Kulasinghe, Wiem Lassoued, Steven Lott, PhD, MB(ASCP)QIHC, James R. Mansfield, Sebastian Marwitz, George J. Netto MD, David Page, Edwin Roger Parra Cuentas, David Rimm, Scott Rodig MD, PhD, Roberto Salgado, Denis Schapiro, Kurt Schalper, Joel C. Sunshin, Michael Surace, Ph.D., Alex Szalay, Magdalena Thurin, Jose C. Villasboas, Keith Wharton, Jr., MD PhD, Ignacio I Wistuba, Jennifer H. Yearley, Yinyin Yuan, George Zaki, James Ziai, and Janis M. Taube.
The purpose of this work was to draw a roadmap for advanced IHC and immunofluorescence assays—particularly multiplex IF—to help standardize reporting, improve reproducibility, and establish a common scientific language in a rapidly evolving field.
Standardization is not about restriction; it is about clarity, comparability, and trust. Ultimately, this effort is about better science, better translation, and—most importantly—better outcomes for the patients these tests are meant to serve.
Grateful to everyone who contributed their expertise, time, and belief in this vision. This is how progress happens—together.
#SITC #Immunotherapy #Pathology #MultiplexIF #IHC #CancerResearch #TranslationalScience #Collaboration #Standards
@JohnsHopkins @